United Therapeutics Corporation
Tyvaso
idiopathic pulmonary fibrosis
Resolved
67days ago
Phase 2 readout · May 1, 2026
What's at stake
Phase 2 trial results for Tyvaso in idiopathic pulmonary fibrosis are due May 1, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 15h ago
“Additional TETON-1 study results and data from the integrated analyses of TETON-1 and TETON-2 will be presented at the American Thoracic Society Annual Meeting in Orlando in May 2026.”